A phase 2 POD1UM-203 trial of retifanlimab in metastatic UC, non-small-cell lung cancer (NSCLC), melanoma, and renal cell carcinoma (RCC) showed antitumor activity similar to other anti-PD-1 ICIs, with an ORR of 37.9%, disease control rate of 55.2%, mPFS of 5.7 months, and mOS of 15.2 months among the 29 patients with mUC [48]. Here, PDCD1 is linked to renal cell carcinoma.